All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Novel Lipo-MIT–Based Triplet Drives Responses in R/R Myeloma

August 15th 2025

Bortezomib plus mitoxantrone hydrochloride liposome and dexamethasone produced responses with manageable safety in relapsed/refractory myeloma

Nemvaleukin Alfa Demonstrates Durable Disease Control in Advanced Melanoma and RCC

August 15th 2025

Nemvaleukin alfa produced a disease control rate of 50% in advanced melanoma and RCC.

Clinical Development Is Discontinued for SGR-2921 in R/R AML and Higher-Risk MDS

August 15th 2025

The development of SGR-2921 in relapsed/refractory AML and higher-risk MDS was discontinued followed by 2 patient deaths.

Early Activity With Roginolisib Supports Ongoing Phase 2 OCULE-01 Trial in Metastatic Uveal Melanoma

August 15th 2025

Early data showing tolerability and improved OS with roginolisib in metastatic uveal melanoma support its ongoing evaluation in the phase 2 OCULE-01 trial.

Understanding Hematology/Oncology Clinical Trials Is Crucial to Patient Communication

August 15th 2025

Matthew Hadfield, DO, discusses how hematology/oncology fellows should approach the interpretation of clinical trial data.

Tailored Therapies Needed to Overcome Immune-Cold Microenvironment of Chromophobe RCC

August 15th 2025

David A. Braun, MD, PhD, discusses the need for more tailored treatments that improve tumor-specific T-cell infiltration in chromophobe RCC.

Real-World Data Highlight Feasibility of CAR T-Cell Therapy in Patients With Aggressive Lymphomas and Active Autoimmune Disease

August 14th 2025

Retrospective data showed CAR T-cell therapy is feasible in patients with aggressive lymphomas and active autoimmune diseases.

SHR-A1811 Monotherapy Generates Similar pCR Rate as PCbHP in HER2+ Breast Cancer

August 14th 2025

The antibody-drug conjugate SHR-A1811 demonstrated a comparable pCR rate to SHR-A1811/pyrotinib and PCbHP in HER2-positive breast cancer.

Declining MCL Incidence Aligns With Broader Lymphoma Trends, But Survival Disparities Persist

August 14th 2025

Ruby Arora, MD, discusses an analysis of SEER data on the declining MCL incidence and disparities that persist in Hispanic and American Indian patients.

Neoadjuvant Vidutolimod Plus Pembrolizumab Displays High pCR Rates in Resectable Melanoma

August 14th 2025

Neoadjuvant vidutolimod plus pembrolizumab showed promising activity in stage III resectable melanoma.

FDA Grants Fast Track Designation to HLD-0915 for Metastatic Castration-Resistant Prostate Cancer

August 14th 2025

HLD-0915 has received fast track designation from the FDA, allowing for more frequent communication with the agency regarding the drug’s candidacy for approval.

Proton Therapy Center Expansion Will Significantly Boost Patient Capacity Across the Mountain West

August 14th 2025

Huntsman Cancer Institute is expanding its proton therapy center, enhancing access to advanced cancer treatment for patients in the Mountain West region.

Immunotherapy and T-Cell–Directed Therapy Expand Treatment Approaches in Small Cell Lung Cancer

August 14th 2025

Sonam Puri, MD, discusses advances in small cell lung cancer that have expanded treatment options across disease stages.

Defects in Antitumor Immunity May Account for Limited Efficacy With Checkpoint Inhibition in Chromophobe RCC

August 14th 2025

David A. Braun, MD, PhD, outlines differences in the tumor biology and immune phenotypes of chromophobe and clear cell renal cell carcinoma.

Phase 3 Evaluation of Sigvotatug Vedotin Is Underway in Pretreated Nonsquamous NSCLC

August 13th 2025

Sigvotatug vedotin is being compared with docetaxel in patients with pretreated NSCLC in the phase 3 Be6A Lung-01 study.

Anlotinib Plus Toripalimab Yields Antitumor Activity in Advanced Soft Tissue Sarcoma and Bone Sarcoma

August 13th 2025

Treatment with the combination of anlotinib and toripalimab produced durable efficacy in soft tissue sarcoma and bone sarcoma.

Fox Chase Cancer Center and Temple Researchers Highlight Need For Molecular Testing in Diagnosing Two Types of Kidney Cancer

August 13th 2025

Genetic testing could help determine differences between rare forms of kidney cancer.

CD19 t-haNK Leads to Complete Responses in Waldenstrom Macroglobulinemia

August 13th 2025

CD19 t-haNK demonstrated complete responses in 2 patients with heavily pretreated Waldenstrom macroglobulinemia.

Health Canada Authorizes Perioperative Pembrolizumab in Resectable, Locally Advanced HNSCC

August 13th 2025

Perioperative pembrolizumab has received the green light for use in combination with radiotherapy with or without cisplatin in PD-L1–positive HNSCC.

Real-World Data Support Tucatinib-Based Treatment in HER2+ Metastatic Breast Cancer

August 13th 2025

Real-world tucatinib-based regimens were effective in different lines for HER2-positive metastatic breast cancer, including after trastuzumab deruxtecan.